Barclays’s Acurx Pharmaceuticals ACXP Stock Holding History

Barclays’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$436	Sell	281 -99	-26%	-$206	﹤0.01%	5028
2026 Q1	$1.41K	Buy	+380	New	+$1.08K	﹤0.01%	4884

Other funds holding ACXP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Barclays's ACXP Position: Q2 2026 in Review

Barclays reduced its Acurx Pharmaceuticals (ACXP) stake by 26% in Q2 2026, selling an estimated $206 and leaving 281 shares worth $436. The position accounts for ﹤0.01% of the portfolio, ranked #5028.

Barclays first reported a position in ACXP in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.41K in Q1 2026. 19 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

Barclays held 281 shares of Acurx Pharmaceuticals worth $436 as of Q2 2026.
Barclays sold 99 Acurx Pharmaceuticals shares in Q2 2026, an estimated $206.
Acurx Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5028 holding.
Barclays first reported a position in Acurx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
Barclays's Acurx Pharmaceuticals position peaked at $1.41K in Q1 2026.
19 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.